Results 171 to 180 of about 165,965 (304)

Interpreting Pregnancy Risk After GLP-1 Receptor Agonists Discontinuation. [PDF]

Diabetes Obes Metab
Scairati R, Newman C, Dunne FP, Colao A.
europepmc   +1 more source

Public Policies in Historical Context and the Association Between Education and US Older Adults’ Health

The Milbank Quarterly, EarlyView.
Policy Points Improving population health while reducing inequality is possible, but it depends on broad institutional investments whose benefits extend across the socioeconomic distribution rather than accruing primarily to the advantaged. The education–health gradient is sensitive to the race between technology and education.
MARK D. HAYWARD, MATEO P. FARINA
wiley   +1 more source

Glucagon‐like peptide‐1 receptor agonist use and violent crime among US adults

Criminology, EarlyView.
Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), a class of medications widely prescribed for diabetes and obesity, have exhibited emerging effects on substance use, reward processing, and impulse control. This study examines whether current GLP‐1 RA use moderates established behavioral pathways to violent crime from impulsivity and ...
Daniel C. Semenza, Christopher Thomas
wiley   +1 more source

Patient Experiences With GLP-1 Receptor Agonists.

JAMA Netw Open
de Vere Hunt I, Ramirez-Posada M, Babu CS, Brown-Johnson C, Linos E, Rodriguez F.   +5 more
europepmc   +1 more source

Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension. [PDF]

ERJ Open Res
Aguado B, Lacoste-Palasset T, Ruffenach G, Bauer F, Savale L, Humbert M, Montani D, Antigny F.   +7 more
europepmc   +1 more source

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jari Tiihonen   +5 more
wiley   +1 more source

The promise of GLP-1 receptor agonists for neurodegenerative diseases. [PDF]

J Clin Invest
Athauda D, Greig NH, Meissner WG, Foltynie T, Gandhi S.   +4 more
europepmc   +1 more source

Cardiometabolic Treatment Gap in Routine Psychiatric Care: A Cross‐Sectional Study of 1553 Patients

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background People with severe mental illness (SMI) have elevated cardiometabolic morbidity and mortality, with similar concerns increasingly reported in other psychiatric conditions including anxiety disorders and ADHD. Somatic conditions are often underdiagnosed and pharmacologically undermanaged in this population.
Vincent Achour, Melanie Faugere, Laurent Boyer, Christophe Lançon, Theo Korchia   +4 more
wiley   +1 more source

The emerging implications of GLP-1 receptor agonists in radiation therapy. [PDF]

Oncologist
Reinicke T, Dilworth JT.
europepmc   +1 more source

Discovery of Small-Molecule GLP‑1 Receptor Agonists with Improved Oral Pharmacokinetics Based on Orforglipron. [PDF]

ACS Med Chem Lett
Li M, Fang J, Qi G, Guo S, Xu T, Lu Y, Yuan Q, Wang J, Zhu S, Shen J, Yang H, Xie X, Wang K.   +12 more
europepmc   +1 more source